EE365 Cost-Minimization and Budget Impact Analysis of Venetoclax Plus Obinutuzumab Compared With Acalabrutinib in the First Line and R/R Chronic Lymphocytic Leukemia From the Brazilian Private Healthcare Perspective
Abstract
Authors
A Marinato A Takao L Campos R Silva S Tanaka